Some two years after splitting biotech company Bluebird Bio into two entities, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.
Comments
(ーー゛)
There's nothing here…
Some two years after splitting biotech company Bluebird Bio into two entities, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.